Navigation Links
Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment

PHILADELPHIA Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

"Our results provide preclinical evidence for the rational combination of BRAF-targeted therapy and immunotherapy in the treatment of this most dangerous type of skin cancer," said lead researcher Jennifer A. Wargo, M.D., division of surgical oncology at Massachusetts General Hospital, Boston.

"By blocking the oncogenic BRAF, tumor antigen expression may be restored. This would make the melanoma tumors susceptible to strategies incorporating immunotherapy," she said.

Previous studies have shown that melanoma treatment with selective BRAF inhibitors are very effective and result in a high initial response rate, but the response is temporary. An alternative approach would be to combine other agents and extend the duration of treatment response.

Using biopsies of melanoma tumors, the researchers investigated the effects of mitogen-activated protein kinase (MAPK) pathway inhibition vs. selective inhibition of BRAF-V600E on T-cell function.

Inhibition of the MAPK pathway with a specific inhibitor of BRAF-V600E resulted in increased expression of antigens, which was associated with improved recognition by antigen-specific T-cell. T-cell function was not compromised after treatment with BRAF-V600E.

Mario Colombo, Ph.D., director of molecular immunology at the Italian National Cancer Institute and senior editor for Cancer Research, said these results advance cancer research by offering new arguments to sustain the combination of selective targeted therapy with immunotherapy.

"This study shows the need for considering the effect of off-targeted drug therapy on the many aspects of host immune response to make real the combination of chemo- and immunotherapy," Colombo said. "It also prompts the idea of performing vaccination in the attempt to eradicate the disease and prevent recurrence."

Several clinical trials are underway using agents that selectively inhibit BRAF-V600E in patients with metastatic melanoma. These studies have shown impressive response rates, though durability of response remains an issue, according to Wargo.

Results of this study provide a basis for combining this type of therapy with immunotherapy, with the goal of improving durability of responses.


Contact: Tara Yates
American Association for Cancer Research

Related medicine news :

1. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
2. New Laser Technology Combined with Manual Physical Therapy Offer Pain Relief to Chronic Pain Sufferers
3. Singapore Performs Asia's First Combined Heart and Liver Transplant
4. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
5. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
6. Combined drug therapy to treat TB and HIV significantly improves survival
7. Combined mammography and breast MRI useful for some high-risk women
8. Green tea chemical combined with another may hold promise for treatment of brain disorders
9. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
10. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
11. FDA Approval of new Prostate Treatment Shows Promise of Cancer Immunotherapy
Post Your Comments:
Related Image:
Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s ... a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is ... different way. The location is scheduled to operate through Dec. 24. , Holiday Pop-Up ...
(Date:11/24/2015)... CT (PRWEB) , ... November 24, 2015 , ... Aided ... (WCHN) today announced an innovative study designed to yield insights into how to detect ... development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester ... University President Carl S. Cleveland III on October 16. , “Katie is very ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Healthy Aging Program have announced their endorsement of the Medical Fitness Network ... Fitness is proud to have the MFN as one of our endorsed organizations,” ...
(Date:11/24/2015)... Warsaw, IN (PRWEB) , ... November 24, 2015 , ... ... in his office to help the community stress less this holiday season. During ... unnecessary additional stress in people's lives and the team at AlignLife want to help ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
(Date:11/24/2015)... November 2015 Avery Biomedical Devices ... ist erfreut, die Berufung von Anders Jonzon, ... zu können.   ... Foto -   ... 1984-1986 war er Fellow des Cardiovascular Institute ...
Breaking Medicine Technology: